CA3247908A1 - Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound - Google Patents

Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound

Info

Publication number
CA3247908A1
CA3247908A1 CA3247908A CA3247908A CA3247908A1 CA 3247908 A1 CA3247908 A1 CA 3247908A1 CA 3247908 A CA3247908 A CA 3247908A CA 3247908 A CA3247908 A CA 3247908A CA 3247908 A1 CA3247908 A1 CA 3247908A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247908A
Other languages
French (fr)
Inventor
Mingzhu JU
Xiaoyan Wang
Jie Wang
Xiaoli Cao
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of CA3247908A1 publication Critical patent/CA3247908A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprising a neurokinin-1 antagonist prodrug compound. A pharmaceutical composition comprising a compound of formula I and a stabilizer, and a preparation method therefor. (see formula I)

Description

[0001] The present application claims the right of priority for:
[0002] CN 202210032508.4, filing date: January 12, 2022. TECHNICAL FIELD
[0003] The present disclosure belongs to the field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition comprising a neurokinin-1 antagonist prodrug compound and a preparation method therefor. BACKGROUND
[0004] Tachykinins are peptide ligands for neurokinin receptors. Neurokinin receptors, such as NK1, NK2 and NK3, are involved in various biological processes. They can be found in the nervous and circulatory systems of mammals, as well as in surrounding tissues. Therefore, the regulation of such receptors has been investigated for potential treatment or prevention of various physiological disorders, conditions or diseases in mammals.
[0005] On the other hand, drug-induced hemolysis is caused by the destruction of a large number of red blood cells due to immune factors after drugs enter the human body, and clinical signs of hemolysis include anemia, jaundice and soy sauce-colored urine. Drug-induced hemolytic anemia can be divided into the following three types: (1) drug-induced immune hemolytic anemia, which results in an antibody-mediated hemolytic reaction; (2) hemolytic anemia caused by the action of drugs on red blood cells with an inherited enzyme deficiency (e.g., G6PD deficiency); (3) hemolytic anemia caused by a drug-induced hemolytic reaction to abnormal hemoglobin. The key to treating this disease is to discontinue the use of related drugs and control the occurrence of hemolysis so as to prevent complications.
[0006] WO 2020259675 provides a new NK1 antagonist prodrug compound (formula I) that is effective in the treatment of various physiological disorders, conditions or diseases with minimal side effects, and that has good pharmaceutical activity.2 . CONTENT OF THE PRESENT INVENTION
[0007] An objective of the present disclosure is to provide a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, which composition has excellent stability.
[0008] An aspect of the present disclosure provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a stabilizer, wherein the stabilizer is an amino acid and/or a saccharide, .
[0009] In some embodiments, the amino acid is an amino acid that contains at least one carboxylic acid group [-C(=O)OH] and at least one primary amino group or secondary amino group [-NH2 or -RNH, wherein -R is a group other than -H] but does not contain a secondary amide group [-C(=O)-NH-]. For example, the amino acid may be one or more of alanine, 4- aminobutyric acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, 8- aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine,3 glycine, histidine, isoleucine, leucine, lysine, methionine, methyllysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
[0010] In some embodiments, the amino acid is a basic amino acid, preferably one or more of arginine, lysine and histidine, and more preferably arginine.
[0011] In some embodiments, the saccharide is selected from one or more of sucrose, glucose, lactose, trehalose and maltose, preferably sucrose and/or glucose, and more preferably glucose.
[0012] In some embodiments, the stabilizer is selected from one or more of arginine, glucose and sucrose, more preferably arginine and/or glucose.
[0013] In some embodiments, the pharmaceutical composition further comprises a solvent. Available solvents include, but are not limited to, water, organic solvents, water/organic solvent cosolvent systems. The organic solvents include, but are not limited to, methanol, ethanol, npropanol, isopropanol, n-butanol, isobutanol, tert-butanol, acetone, acetonitrile, dichloromethane, dimethyl sulfoxide, etc. Preferred solvents may be water, ethanol, isopropanol, tert-butanol, water/ethanol, water/isopropanol, water/tert-butanol, etc.
[0014] In some embodiments, the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the stabilizer is 1 : 0.1-1 : 20, e.g., 1 : 0.1, 1 : 0.2, 1 : 0.3, 1 : 0.4, 1 : 0.5, 1 : 0.6, 1 : 0.7, 1 : 0.8, 1 : 0.9, 1 : 1, 1 : 2, 1 : 3, 1 : 4, 1 : 5, 1 : 6, 1 : 7, 1 : 8, 1 : 9, 1 : 10, 1 : 11, 1 : 12, 1 : 13, 1 : 14, 1 : 15, 1 : 16, 1 : 17, 1 : 18, 1 : 19, 1 : 20 or any value therebetween, preferably 1 : 1-1 : 10, and more preferably 1 : 1-1 : 7.5.
[0015] In some embodiments, the compound of formula I or the pharmaceutically acceptable salt thereof has a mass volume percentage of 0.01%-30%, e.g., 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30% or any value therebetween, preferably 0.01%-10%, and more preferably 0.1%- 5%.
[0016] In some embodiments, the stabilizer has a mass volume percentage of 0.01%-30%, e.g., 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30% or any value therebetween, preferably 0.01%-20%, and more preferably 0.1%-10%.
[0017] In some embodiments, the pharmaceutical composition further comprises a buffer. The buffer may be a phosphate buffer, a citrate buffer, an acetate buffer, a succinate buffer, a4 histidine salt buffer or other organic acid salt buffers.
[0018] In some embodiments, the buffer has a concentration of 5 mM-40 mM, preferably 10 mM-30 mM.
[0019] In some embodiments, the pharmaceutical composition may further comprise a pH regulator. The pH regulator includes, but is not limited to, sodium hydroxide, hydrochloric acid, etc.
[0020] In some embodiments, the pharmaceutical composition further comprises a chelating agent. The chelating agent is selected from ethylenediamine tetraacetic acid or a salt thereof.
[0021] In some embodiments, the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the chelating agent is 1000 : 1-1 : 1, e.g., 1000 : 1, 900 : 1, 800 : 1, 700 : 1, 600 : 1, 500 : 1, 400 : 1, 300 : 1, 200 : 1, 100 : 1, 90 : 1, 80 : 1, 70 : 1, 60 : 1, 50 : 1, 45 : 1, 40 : 1, 35 : 1, 30 : 1, 25 : 1, 20 : 1, 15 : 1, 10 : 1, 9 : 1, 8 : 1, 7 : 1, 6 : 1, 5 : 1, 4 : 1, 3 : 1, 2 : 1, 1 : 1 or any value therebetween, more preferably 1000 : 1-10 : 1. In some embodiments, the chelating agent has a mass volume percentage of 0.001%-5%, preferably 0.01%-2%.
[0022] In some embodiments, the pharmaceutical composition has a pH value of 3.0-8.0, e.g., 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0 or any value therebetween, preferably 5.0-8.0.
[0023] In some embodiments, the pharmaceutical composition further comprises a 5-HT3 receptor antagonist selected from granisetron, ondansetron, ramosetron, tropisetron, palonosetron or dolasetron, preferably palonosetron.
[0024] In some embodiments, the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the 5-HT3 receptor antagonist is 2000 : 1-10 : 1, e.g., 2000 : 1, 1900 : 1, 1800 : 1, 1700 : 1, 1600 : 1, 1500 : 1, 1400 : 1, 1300 : 1, 1200 : 1, 1100 : 1, 1000 : 1, 900 : 1, 800 : 1, 700 : 1, 600 : 1, 500 : 1, 400 : 1, 300 : 1, 200 : 1, 100 : 1, 90 : 1, 80 : 1, 70 : 1, 60 : 1, 50 : 1, 45 : 1, 40 : 1, 35 : 1, 30 : 1, 25 : 1, 20 : 1, 15 : 1, 10 : 1 or any value therebetween, preferably 1000 : 1-100 : 1. In some embodiments, the 5-HT3 receptor antagonist has a mass volume percentage of 0.0001%-1%, e.g., 0.0001%, 0.001%, 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1% or any value therebetween, preferably 0.0001%-0.1%.
[0025] In some embodiments, the pharmaceutical composition comprises (based on mass5 volume percentage): [0026] 0.01%-10% of a compound of formula I or a pharmaceutically acceptable salt thereof; [0027] 0.01%-20% of a stabilizer selected from one or more of arginine, glucose and sucrose; [0028] optionally 0.0001%-1% of palonosetron or a pharmaceutically acceptable salt thereof; [0029] optionally a 5 mM-40 mM buffer; [0030] optionally 0.01%-2% of a chelating agent; and [0031] 70%-99% of a solvent selected from water and/or tert-butanol.
[0032] The pharmaceutical composition may have a pH value of 3.0-8.0, preferably 5.0-8.0. The pharmaceutical composition may optionally further comprise a pH regulator, etc.
[0033] The present disclosure further provides a sterile powder obtained by freeze-drying or spray-drying the pharmaceutical composition of the present disclosure.
[0034] The present disclosure further provides a sterile powder, which is reconstituted to obtain the pharmaceutical composition of the present disclosure.
[0035] In some embodiments, the sterile powder of the present disclosure contains less than 5% of prototype drug impurities, and the content thereof may be less than 4.9%, 4.8%, 4.7%, 4.6%, 4.5%, 4.4%, 4.3%, 4.2%, 4.1%, 4.0%, 3.9%, 3.8%, 3.7%, 3.6%, 3.5%, 3.4%, 3.3%, 3.2%, 3.1%, 3.0%, 2.9%, 2.8%, 2.7%, 2.6%, 2.5%, 2.4%, 2.3%, 2.2%, 2.1%, 2.0% or less.
[0036] In some embodiments, the sterile powder of the present disclosure contains less than 5% of prototype drug impurities after being placed at 25 oC and 60% RH for 30 days, and the content thereof may be less than 4.9%, 4.8%, 4.7%, 4.6%, 4.5%, 4.4%, 4.3%, 4.2%, 4.1%, 4.0%, 3.9%, 3.8%, 3.7%, 3.6%, 3.5%, 3.4%, 3.3%, 3.2%, 3.1%, 3.0%, 2.9%, 2.8%, 2.7%, 2.6%, 2.5%, 2.4%, 2.3%, 2.2%, 2.1%, 2.0% or less.
[0037] The present disclosure further provides a reconstituted solution obtained by reconstituting the sterile powder of the present disclosure.
[0038] In some embodiments, the reconstituted solution is an injectable composition.
[0039] The reconstituted solution may have a pH value of 3.0-8.0, preferably 5.0-8.0. The reconstituted solution may use water for injection, physiological saline, a glucose solution, etc.
[0040] The present disclosure further provides a method for preparing the pharmaceutical composition of the present disclosure, wherein the method comprises the step of mixing a compound of formula I or a pharmaceutically acceptable salt thereof with a stabilizer.6
[0041] In some embodiments, the method further comprises the step of drying the composition comprising the compound of formula I or the pharmaceutically acceptable salt thereof and the stabilizer. The drying method may be selected from freeze-drying or spraydrying.
[0042] In some embodiments, the stabilizer is formulated in the form of a solution. Preferably, the stabilizer solution has a pH < 7.
[0043] The compound of formula I or the pharmaceutically acceptable salt thereof of the present disclosure may be a compound of formula I in any form, specific forms including, but not limited to, amorphous form, any crystal form, hydrate, solvate, etc.
[0044] The present disclosure further provides the use of the aforementioned pharmaceutical composition, sterile powder or reconstituted solution in the preparation of a drug for treating physiological disorders, conditions or diseases in a patient, wherein the physiological disorders, conditions or diseases are preferably respiratory diseases, cough, inflammatory diseases, skin disorders, ophthalmic disorders, depression, anxiety, phobia, bipolar disorder, alcohol dependence, neuroactive substance abuse, epilepsy, nociception, psychosis, schizophrenia, Alzheimer's disease, AIDS-related dementia, Towne's disease, stress-related disorders, obsessive/compulsive disorders, bulemia, anorexia nervosa, binge eating, mania, premenstrual syndrome, gastrointestinal dysfunction, atherosclerosis, fibrotic disorder, obesity, type II diabetes, headache, neuropathic pain, post-exercise pain, chronic pain syndrome, bladder disorders, urogenital disorders, vomiting or nausea.
[0045] The "mass volume percentage" (w/v) of the present disclosure refers to the mass (in g) of the component contained per 100 mL of a liquid system, i.e., g/100 mL.
[0046] The content (including percentage content) of various substances and the ratios of the various substances to each other of the present disclosure all have an allowable error of ± 5%. For example, the expression "the content of the compound of formula I or the pharmaceutically acceptable salt thereof in the composition is 5 to 20 mg/mL" means that the content of the compound of formula I or the pharmaceutically acceptable salt thereof in the composition is 4.75 to 21 mg/mL, which falls within the scope of the present disclosure; the expression "the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the stabilizer is selected from 1 : 1 to 1 : 100" means that the weight ratio of the compound of7 formula I or the pharmaceutically acceptable salt thereof to the stabilizer is selected from 1 : 0.95 to 1 : 105, which falls within the scope of the present disclosure.
[0047] The expressions "mixing...into..." and "mixing... with..." of the present disclosure mean that the adding sequence of components is not limited. For example, "mixing A into B" can mean adding A to B, and can also mean adding B to A, and "mixing A with B" can mean adding A to B for mixing, and can also mean adding B to A for mixing. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0048] Example 1
[0049] According to the ratio (w/v) in the table below, 90% of the target volume of a solvent was taken, a prescription amount of a stabilizer was added to the solvent, the pH of the resulting solution was adjusted with hydrochloric acid to pH < 7, to the solution was added the raw material of the compound of formula I, and the resulting mixture was stirred for dissolution at room temperature. The pH was adjusted with dilute hydrochloric acid or sodium hydroxide, filtration was performed with a 45 μm organic filtration membrane to obtain a clear solution, and the volume of the clear solution was made up to with the solvent. The above-mentioned solution was stored at 4 oC before subpackaging. After subpackaging according to the target volume, half of a stopper was pressed, and a freeze-drying procedure was run. After the completion of the procedure, nitrogen was filled, the remaining stopper was pressed, and the freeze-dried compounds were taken out of the box. No. Content of compound of formula I Stabilizer Content of stabilizer Solvent system System pH Other auxiliary materials 1 2% Sucrose 5% Water 8 2 2% Glucose 5% Water 8 3 2% Lactose 2% Water 8 4 2% Arginine 5% Water 8 5 2% Histidine 2% Water 8 6 2% Proline 5% Water 8 7 2% SBECD 5% Water 88 8 2% Hydroxyethyl starch 2% Water 8 9 2% PEG 4000 2% Water 8 10 2% PVP K12 2% Water 8 11 2% Dextran 40k 2% Water 8 12 4.36% Trehalose 5% 50% TBA 5 13 4.36% Mannitol 5% 50% TBA 5 14 4.35% NADA 8% 50% TBA 5 15 3.00% Maltose 5% 50% TBA 5 16 3.0% Arginine 5% 50% TBA 5 20 mM citrate buffer 17 2.1% Arginine 5% Water 8 0.05% EDTA-2NaCa 18 3.00% Arginine 5% 50% TBA 3 19 3.00% Arginine 5% 50% TBA 4 20 3.00% Arginine 5% 50% TBA 5 21 3.00% Arginine 5% 50% TBA 6 22 3.00% Arginine 5% 50% TBA 7 23 3.00% Arginine 5% 50% TBA 8 24 3.00% Sucrose 5% 50% TBA 5 25 3.00% Sucrose 5% 50% TBA 8 26 3.00% Glucose 3% 50% TBA 5 27 3.00% Glucose 3% 50% TBA 8 [0050] 50% TBA: 50% aqueous tert-butanol solution; SBECD: sulfobutylether-β- cyclodextrin; PVP: polyvinylpyrrolidone; NADA: N-acetyl-D-alanine
[0051] Example 2
[0052] The preparation samples prepared in example 1 were placed under accelerated conditions (25 oC, 60% RH), and were detected for the active substance and impurity content. Detection method: detection was performed by a high performance liquid chromatography system, wherein the chromatographic column was ACE Excel 3 SuperC18, 4.6 × 150 mm, 3 μm, the mobile phase A was 0.01 mol/L potassium dihydrogen phosphate solution-pH 7.0, the mobile phase B was acetonitrile, and the detection wavelength was 210 nm.9
[0053] The detection results are as shown in the table below. The prototype drug impurity is rolapitant formed by the degradation of the compound of formula I. No. Stabilizer Stability condition Purity (%) Prototype drug impurity (%) 1 Sucrose 0 0 d 99.33 0.46` 25 oC/60% RH 14 d 98.82 0.94 30 d 98.54 1.24 60 d 98.19 1.63 2 Glucose 0 0 d 99.42 0.36 25 oC/60% RH 14 d 99.38 0.48 30 d 99.15 0.72 60 d 98.47 1.37 90 d 97.73 1.89 3 Lactose 0 0 d 98.4 1.04 25 oC/60% RH 14 d 95.38 3.16 4 Arginine 0 0 d 99.43 0.37 25 oC/60% RH 14 d 99.25 0.57 30 d 99.14 0.69 60 d 98.92 0.89 90 d 98.83 0.98 5 Histidine 0 0 d 98.37 1.12 25 oC/60% RH 14 d 94.58 3.89 90 d 88.43 9.01 6 Proline 0 0 d 99.39 0.43 25 oC/60% RH 14 d 96.53 2.79 90 d 50.71 40.80 7 SBECD 0 0 d 93.28 3.6 25 oC/60% RH 14 d 81.15 10.92 90 d 63.95 22.77 8 Hydroxyethyl starch 0 0 d 91.90 3.83 25 oC/60% RH 14 d 82.069 9.55 9 PEG 4000 0 0 d 90.44 4.74 25 oC/60% RH 14 d 78.772 10.881 10 PVP K12 0 0 d 88.20 5.81 25 oC/60% RH 14 d 86.121 / 11 Dextran 40k 0 0 d 92.79 3.59 25 oC/60% RH 14 d 82.914 9.16810 12 Trehalose 0 0 d 99.087 0.504 25 oC/60% RH 7 d 98.36 1.06 14 d 97.63 1.58 13 Mannitol 0 0 d 98.949 0.494 25 oC/60% RH 7 d 98.09 1.03 14 d 97.19 1.56 14 NADA 0 0 d 98.87 0.39 25 oC/60% RH 7 d 97.85 1.01 14 d 97.15 1.45 30 d 95.65 2.36 15 Maltose 0 0 d 99.24 0.41 25 oC/60% RH 7 d 98.48 0.91 14 d 97.80 1.42 30 d 96.95 2.03 16 Arginine 0 0 d 99.19 0.43 25 oC/60% RH 7 d 99.13 0.51 14 d 98.91 0.63 30 d 98.72 0.74 60 d 98.34 0.97 90 d 98.12 1.21 17 Arginine 0 0 d 99.53 0.38 25 oC/60% RH 7 d 98.88 0.90 14 d 98.81 0.95 30 d 99.10 0.78 90 d 98.72 1.00 18 Arginine 0 0 d 99.21 0.40 25 oC/60% RH 07 d 98.86 0.64 14 d 98.49 0.76 30 d 97.95 1.24 60 d 97.33 1.82 90 d 96.51 2.74 19 Arginine 0 0 d 99.24 0.41 25 oC/60% RH 07 d 98.92 0.63 14 d 98.61 0.80 30 d 98.31 1.01 60 d 97.72 1.44 90 d 97.10 1.9911 20 Arginine 0 0 d 99.24 0.40 25 oC/60% RH 07 d 98.94 0.60 14 d 98.71 0.75 30 d 98.36 0.96 60 d 97.75 1.37 90 d 97.25 1.88 21 Arginine 0 0 d 99.25 0.39 25 oC/60% RH 07 d 98.96 0.58 14 d 98.78 0.69 30 d 98.31 1.02 60 d 97.86 1.36 90 d 97.84 1.4 22 Arginine 0 0 d 99.27 0.37 25 oC/60% RH 07 d 98.92 0.61 14 d 98.75 0.88 30 d 98.34 1.06 60 d 97.88 1.40 90 d 97.56 1.76 23 Arginine 0 0 d 99.20 0.43 25 oC/60% RH 07 d 98.69 0.80 14 d 98.60 0.89 30 d 98.32 1.11 60 d 97.58 1.64 90 d 97.24 2.02 24 Sucrose 0 0 d 99.25 0.39 25 oC/60% RH 07 d 98.53 0.94 14 d 98.08 1.34 30 d 97.22 1.98 25 Sucrose 0 0 d 98.74 0.69 25 oC/60% RH 07 d 97.58 1.53 14 d 96.61 2.18 30 d 95.91 2.76 26 Glucose 0 0 d 99.24 0.41 25 oC/60% RH 07 d 98.97 0.62 14 d 98.63 0.90 30 d 98.03 1.23 60 d 97.34 1.8512 90 d 95.82 3.37 27 Glucose 0 0 d 98.95 0.58 25 oC/60% RH 07 d 97.95 1.26 14 d 97.93 1.31 30 d 97.35 1.70 60 d 97.40 1.87 90 d 96.17 2.71
[0054] After being placed under accelerated conditions, the freeze-dried preparations in which the stabilizers are sucrose, glucose and arginine have little change in purity, and are low in the prototype drug impurity from degradation, indicating good stability.
[0055] Example 3
[0056] A compound freeze-dried preparation comprising the compound of formula I and palonosetron hydrochloride was prepared using the method of example 1 according to the ratio (w/v) in the table below. No. Content of compound of formula I Content of palonosetron hydrochloride Stabilizer Solvent system System pH Buffer Chelating agent 1 3.11% 0.004011% 5% Arginine Water 6.5 20 mM Citrate 0.5% EDTA- 2NaCa
[0057] Example 4
[0058] The preparation sample prepared in example 3 was placed under accelerated conditions (25 oC, 60% RH), and was detected for the active substance and impurity content. The results are as shown in the table below. No. Stability condition Total impurity content (%) Prototype drug impurity (%) 1 0 0 d 1.18 0.37 25 oC/60% RH 7 d 1.32 0.53 1 M 1.42 0.82 2 M 1.48 1.07 .

Claims (23)

  1. What is claimed is: 1. A pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a stabilizer, wherein the stabilizer is an amino acid and/or a saccharide, .
  2. 2. The pharmaceutical composition according to claim 1, wherein the amino acid is an amino acid that contains at least one carboxylic acid group and at least one primary amino group or secondary amino group but does not contain a secondary amide group, preferably alanine, 4-aminobutyric acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6- aminohexanoic acid, 8-aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, methyllysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
  3. 3. The pharmaceutical composition according to claim 1, wherein the amino acid is a basic amino acid, preferably arginine, lysine and histidine, and more preferably arginine.
  4. 4. The pharmaceutical composition according to any one of claims 1-3, wherein the saccharide is selected from one or more of sucrose, glucose, lactose, trehalose and maltose, preferably sucrose and/or glucose, and more preferably glucose.
  5. 5. The pharmaceutical composition according to claim 1, wherein the stabilizer is14 selected from one or more of arginine, glucose and sucrose, more preferably arginine and/or glucose.
  6. 6. The pharmaceutical composition according to any one of claims 1-5, wherein the pharmaceutical composition further comprises a solvent, preferably the solvent is selected from water, an organic solvent or a water/organic solvent cosolvent system, and more preferably the solvent is selected from water, ethanol, isopropanol, tert-butanol, water/ethanol, water/isopropanol or water/tert-butanol.
  7. 7. The pharmaceutical composition according to any one of claims 1-6, wherein the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the stabilizer is 1 : 0.1-1 : 20, preferably 1 : 1-1 : 10, and more preferably 1 : 1-1 : 7.5.
  8. 8. The pharmaceutical composition according to claim 6, wherein the compound of formula I or the pharmaceutically acceptable salt thereof has a mass volume percentage of 0.01%-30%, preferably 0.01%-10%, and more preferably 0.1%-5%.
  9. 9. The pharmaceutical composition according to any one of claims 6-8, wherein the stabilizer has a mass volume percentage of 0.01%-30%, preferably 0.01%-20%, and more preferably 0.1%-10%.
  10. 10. The pharmaceutical composition according to any one of claims 1-9, wherein the pharmaceutical composition further comprises a buffer, the buffer is preferably a phosphate buffer, a citrate buffer, an acetate buffer, a succinate buffer, a histidine salt buffer or other organic acid salt buffers, and preferably the buffer has a concentration of 5 mM-40 mM, more preferably 10 mM-30 mM.
  11. 11. The pharmaceutical composition according to any one of claims 1-10, wherein the pharmaceutical composition further comprises a pH regulator.15
  12. 12. The pharmaceutical composition according to any one of claims 1-11, wherein the pharmaceutical composition further comprises a chelating agent, preferably the chelating agent is ethylenediamine tetraacetic acid or a salt thereof, preferably the chelating agent has a mass volume percentage of 0.001%-5%, more preferably 0.01%-2%, and preferably the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the chelating agent is 1000 : 1-1 : 1, more preferably 1000 : 1-10 : 1.
  13. 13. The pharmaceutical composition according to any one of claims 1-12, wherein the pharmaceutical composition has a pH value of 3.0-8.0, preferably 5.0-8.0.
  14. 14. The pharmaceutical composition according to any one of claims 1-13, wherein the pharmaceutical composition further comprises a 5-HT3 receptor antagonist, preferably the 5- HT3 receptor antagonist is selected from granisetron, ondansetron, ramosetron, tropisetron, palonosetron or dolasetron, more preferably palonosetron, preferably the 5-HT3 receptor antagonist has a mass volume percentage of 0.0001%-1%, more preferably 0.0001%-0.1%, and preferably the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the 5-HT3 receptor antagonist is 2000 : 1-10 : 1, more preferably 1000 : 1-100 : 1.
  15. 15. The pharmaceutical composition according to any one of claims 1-14, comprising: a compound of formula I or a pharmaceutically acceptable salt thereof; a stabilizer selected from one or more of arginine, glucose and sucrose; optionally palonosetron or a pharmaceutically acceptable salt thereof; optionally a buffer; optionally a chelating agent.
  16. 16. The pharmaceutical composition according to any one of claims 1-14, comprising: 0.01%-10% of a compound of formula I or a pharmaceutically acceptable salt thereof; 0.01%-20% of a stabilizer selected from one or more of arginine, glucose and sucrose; optionally 0.0001%-1% of palonosetron or a pharmaceutically acceptable salt thereof;16 optionally a 5 mM-40 mM buffer; optionally 0.01%-2% of a chelating agent; 70%-99% of a solvent selected from water and/or tert-butanol; the percentages are based on mass volume percentages.
  17. 17. A sterile powder obtained by freeze-drying or spray-drying the pharmaceutical composition according to any one of claims 1-16.
  18. 18. A sterile powder, which is reconstituted to obtain the pharmaceutical composition according to any one of claims 1-16.
  19. 19. The sterile powder according to claim 17 or 18, wherein the sterile powder contains less than 5% of prototype drug impurities, preferably less than 4%, more preferably less than 3%, and most preferably less than 2%.
  20. 20. The sterile powder according to claim 17 or 18, wherein the sterile powder contains less than 5% of prototype drug impurities after being placed at 25 oC and 60% RH for 30 days.
  21. 21. A reconstituted solution obtained by reconstituting the sterile powder according to any one of claims 17-20.
  22. 22. A method for preparing the pharmaceutical composition according to any one of claims 1-16, wherein the method comprises the step of mixing a compound of formula I or a pharmaceutically acceptable salt thereof with a stabilizer.
  23. 23. Use of the pharmaceutical composition according to any one of claims 1-16, the sterile powder according to any one of claims 17-20 or the reconstituted solution according to claim 21 in the preparation of a drug for treating physiological disorders, conditions or diseases in a patient, wherein the physiological disorders, conditions or diseases are preferably respiratory diseases, cough, inflammatory diseases, skin disorders, ophthalmic disorders, depression,17 anxiety, phobia, bipolar disorder, alcohol dependence, neuroactive substance abuse, epilepsy, nociception, psychosis, schizophrenia, Alzheimer's disease, AIDS-related dementia, Towne's disease, stress-related disorders, obsessive/compulsive disorders, bulemia, anorexia nervosa, binge eating, mania, premenstrual syndrome, gastrointestinal dysfunction, atherosclerosis, fibrotic disorder, obesity, type II diabetes, headache, neuropathic pain, post-exercise pain, chronic pain syndrome, bladder disorders, urogenital disorders, vomiting or nausea.
CA3247908A 2022-01-12 2023-01-12 Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound Pending CA3247908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210032508 2022-01-12
CN202210032508.4 2022-01-12
PCT/CN2023/071901 WO2023134725A1 (en) 2022-01-12 2023-01-12 Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound

Publications (1)

Publication Number Publication Date
CA3247908A1 true CA3247908A1 (en) 2025-07-10

Family

ID=87280118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247908A Pending CA3247908A1 (en) 2022-01-12 2023-01-12 Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound

Country Status (8)

Country Link
US (1) US20260183319A1 (en)
EP (1) EP4464320B1 (en)
JP (1) JP2025500688A (en)
KR (1) KR20240134358A (en)
CN (1) CN118510509A (en)
CA (1) CA3247908A1 (en)
TW (1) TW202332428A (en)
WO (1) WO2023134725A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464230B1 (en) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
WO2019038656A1 (en) * 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd Novel triple combination formulations for antiemetic therapy
US20190358249A1 (en) * 2018-05-22 2019-11-28 Navinta Iii Inc Injectable Combination Products Of Fosaprepitant And 5-HT3 Blocker
CN111388657B (en) * 2019-01-03 2023-04-07 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing bivalirudin and preparation method thereof
KR102940508B1 (en) 2019-06-28 2026-03-16 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 Neurokinin-1 antagonist

Also Published As

Publication number Publication date
EP4464320C0 (en) 2026-06-24
CN118510509A (en) 2024-08-16
WO2023134725A1 (en) 2023-07-20
US20260183319A1 (en) 2026-07-02
EP4464320B1 (en) 2026-06-24
TW202332428A (en) 2023-08-16
EP4464320A1 (en) 2024-11-20
EP4464320A4 (en) 2025-05-14
KR20240134358A (en) 2024-09-09
JP2025500688A (en) 2025-01-09

Similar Documents

Publication Publication Date Title
EP1347760B1 (en) Nmda receptor agonist pharmaceutical compositions
US12303500B2 (en) Method for improving stability of low-concentration atropine ophthalmic preparation
US20190105392A1 (en) Caspofungin Acetate Formulations
CN112805238A (en) Anhydrous sodium thiosulfate and formulations thereof
US12060439B2 (en) Polymorph of echinocandin antifungal agent
RU2768482C1 (en) Pharmaceutical composition of kappa opioid receptor agonist
CN102784382B (en) Argatroban pharmaceutical composition, and preparation method and application thereof
EP4019033B1 (en) Injectable solution comprising a spirofused tetrapeptide an a ph-regulator for treating kappa opioid receptor-associated conditions
CN103553996B (en) Anticholinergic pharmaceutical composition
EP4014965A1 (en) Aqueous solution
WO2012013116A1 (en) Pharmaceutical composition of temozolomide comprising amino acid stabilizer and preparation method thereof
EP4464320A1 (en) Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound
WO2017185030A1 (en) Caspofungin formulation with low impurities
JP7855696B2 (en) Pharmaceutical composition containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazoline-4-yl]acetate and potassium ions
EP4601616A1 (en) Liquid dalbavancin composition
WO2024079223A1 (en) Liquid dalbavancin composition
JP4875205B2 (en) Stable preparation of thiadiazole derivatives
EP4609874A1 (en) Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition
CN103845725A (en) Relatively stable caspofungin composition
CN114306342A (en) Pharmaceutical composition of imatinib salt for injection and preparation method thereof
HK1215668B (en) Caspofungin acetate formulations
TW201302755A (en) Pharmaceutical composition of Temozolomide comprising amino acid stabilizer and preparation method thereof
HK1141238B (en) Stable formulations of thiadiazole derivative

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240709

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241217

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241217

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250130

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250710

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251218